Retatrutide timeline
Current statusInvestigational. New TRANSCEND-T2D-2 compares retatrutide with Ozempic 2 mg in type 2 diabetes, adding to distinct obesity and OSA reports. The efficacy estimand, open-label design and increased discontinuations matter; the trial does not establish superiority to tirzepatide or cardiovascular benefit.
Dose-specific knee-pain estimates
Original ACR abstracts add efficacy-estimand WOMAC pain changes in TRIUMPH-4 and the TRIUMPH-1 knee-OA substudy. These are newly appraised details of previously reported trials.
On the 0–10 pain scale, 68-week TRIUMPH-4 changes were −4.48/−4.41 at 9/12 mg versus −2.43 with placebo (445 randomized). The 574-person TRIUMPH-1-OA substudy reports 80-week changes of −3.66/−4.19/−4.30 at 4/9/12 mg versus −2.24 with placebo. No confidence intervals appeared in the retrieved text. Full arm-specific harms tables remain an appraisal gap. These findings do not establish cartilage repair, avoided joint replacement or a weight-independent benefit.